Journal article icon

Journal article : Review

Precision, prevention and progress: charting two decades of change in gynaecological oncology-a narrative review

Abstract:
Background and objectiveThe field of Gynaecological Oncology (GO) has undergone a paradigm shift over recent decades, shaped by advancements in prevention, molecular therapeutics, and surgical innovation. We explore how the management of gynaecological malignancies has transformed in the past 25 years.MethodsA structured narrative review of landmark publications and guideline updates published between 2000 and 2025 was undertaken. Key developments in the management of cervical, ovarian, endometrial, vulvar, and vaginal cancers were critically analysed, with particular focus on prevention strategies, surgical evolution, and integration of targeted and immune therapies.Key content and findingsIn cervical cancer, population-level human papillomavirus (HPV) vaccination has dramatically reduced incidence, while the LACC and SHAPE trials prompted a return to open and less radical surgery, respectively. Sentinel node biopsy is supplanting systematic lymphadenectomy, and combined chemoradiotherapy (CRT) with immunotherapy is improving survival in locally advanced disease. For ovarian cancer, optimal cytoreduction remains key, with TRUST highlighting surgical quality, while heated intraperitoneal chemotherapy (HIPEC) and poly-ADP ribose polymerase (PARP) inhibitors-alone or combined with immunotherapy-extend progression-free survival (PFS). Endometrial cancer management is now driven by molecular classification [The Cancer Genome Atlas (TCGA)/Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE)], with immunotherapy and targeted therapy transforming outcomes. In vulvar and vaginal cancers, GROINSS-V (Groin Sentinel Node Trial in Vulvar Cancer) and related studies underpin de-escalated and minimally invasive nodal surgery, while immunotherapy emerges for advanced disease.ConclusionsModern GO is defined by prevention, precision, and personalisation. The contemporary Gynaecological Oncologist now integrates molecular insight, function-preserving surgery, and multidisciplinary collaboration to deliver optimised, patient-centred care.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.21037/tcr-2025-1-2924

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0009-0000-1228-1602
More by this author
Role:
Author
ORCID:
0009-0009-0638-9452
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0009-0004-2831-2134
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Role:
Author
ORCID:
0000-0001-7065-2432


Publisher:
AME Publishing
Journal:
Translational Cancer Research More from this journal
Volume:
15
Issue:
4
Pages:
343
Publication date:
2026-04-28
DOI:
EISSN:
2219-6803
ISSN:
2218676X, 2218-676X
Pmid:
42180877


Language:
English
Keywords:
Subtype:
Review
Source identifiers:
4104282
Deposit date:
2026-06-02
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP